← All trials
NCT05236621
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 4, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Dec 31, 2023
- First posted
- Feb 11, 2022
- Last posted
- Feb 11, 2022
- Enrollment
- 85
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Inner Mongolia Medical UniversityOverall official - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Xinjiang Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- First People's Hospital of FoshanOverall official - principal investigator
- Guangzhou Medical UniversityOverall official - principal investigator
- Guizhou Medical UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Liaocheng People's HospitalOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- Shandong UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Qingdao UniversityOverall official - principal investigator
- Guangzhou Medical UniversityOverall official - principal investigator
- Nanhua UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Weifang People's HospitalOverall official - principal investigator
- Weihai Central HospitalOverall official - principal investigator
- Wuxi People's HospitalOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Cancer Hospital of Yunnan provincealOverall official - principal investigator
- Zhangzhou Municipal Hospital of Fujian ProvinceOverall official - principal investigator
- Xiamen UniversityOverall official - principal investigator
- Capital Medical UniversityOfficial
- Nanhua UniversityOfficial
- Wuxi People's HospitalOfficial
- Guizhou Medical UniversityOfficial
- Jiao Tong UniversityOfficial
- Jiao Tong UniversityOfficial
- Zhangzhou Municipal Hospital of Fujian ProvinceOfficial
- Sun Yat-Sen UniversityOfficial
- Liaocheng People's HospitalOfficial
- First People's Hospital of FoshanOfficial
- Guangzhou Medical UniversityOfficial
- Guangzhou Medical UniversityOfficial
- Hebei UniversityOfficial
- Hebei UniversityOfficial
- Weihai Central HospitalOfficial
- Weifang People's HospitalOfficial
- Xiamen UniversityOfficial
- Henan Medical UniversityOfficial
- Peking UniversityOfficial
- Shandong UniversityOfficial
- Zhejiang UniversityOfficial
- Zhejiang UniversityOfficial
- Shanxi Medical UniversityOfficial
- Shanxi Medical UniversityOfficial
- China Medical UniversityOfficial
- Inner Mongolia Medical UniversityOfficial
- Qingdao UniversityOfficial
- Cancer Hospital of Yunnan provincealOfficial
- Xinjiang Medical UniversityOfficial
- Sichuan UniversityOfficial
- Shengjing HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.